Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide is a synthetic small molecule belonging to the biphenyl and sulfonamide chemical classes. It has been studied as an experimental compound, with no current approved indications or clinical use. The compound has been structurally characterized in protein-ligand complexes, notably in studies involving matrix metalloproteinases (MMPs), suggesting it may act as an inhibitor of these enzymes. However, there are no published clinical trials or marketed products containing this molecule[1][4][5]. Its mechanism of action is presumed to involve inhibition of MMP activity via chelation at the active site zinc ion, but this remains to be fully validated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide.